FDA 483 - Takeda Pharmaceutical Company Limited - July 19, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Takeda Pharmaceutical Company Limited in Yamaguchi, Japan, revealed critical deficiencies in sterile drug product manufacturing and quality control. The firm failed to adequately simulate critical interventions during media fills and exhibited inadequate environmental monitoring in aseptic processing areas. Additionally, the quality control unit did not fully adhere to its procedures, and the company lacked proper controls for incoming components, resulting in foreign particle contamination.
ID · 116551bc-ee0b-45cf-ba4f-c6c4be7fe3d5